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 Abstract 
 
Background. Bipolar disorders are often not recognized. Several screening tools have been 
developed, e.g. the Hypomania Checklist – 32 (HCL-32) and the Mood Disorder 
Questionnaire (MDQ) to improve this situation. Whereas the German HCL-32 has been used 
in non-clinical samples, neither the HCL-32 nor the MDQ have been validated in German 
samples of mood-disordered patients. Additionally, hardly any prior study has included 
patients with non-mood disorders or has considered potential effects of comorbid conditions. 
Therefore the goal of this study was to test the validity of both scales in a diverse patient 
sample while also taking into account psychiatric comorbidity. Method. A multi-site study 
was conducted involving seven centers. Patients (n = 488) completed the HCL-32 and MDQ 
and were independently interviewed with the Structured Clinical Interview for DSM (SCID). 
Results. Sensitivity for bipolar I was similar for HCL-32 and MDQ (.88 and .84) but slightly 
different for bipolar II (.90 and .83), specificity, however, was higher for MDQ. In general, a 
comorbid condition led to increased scores in both tools regardless of whether the primary 
diagnosis was bipolar or not. Limitations & Discussion. Although we included not just mood-
disordered patients, detailed subgroup analyses for all diagnostic categories were not possible 
due to sample sizes. In summary, HCL-32 and MDQ seem fairly comparable in detecting 
bipolar disorders although their effectiveness depends on the goal of the screening, 
psychiatric comorbidity, and potentially the setting.  
 
Keywords: Bipolar disorders, Hypomania, Screening, HCL-32, MDQ, comorbidity, 
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 Introduction 
 
 
Mood disorders, especially depression, are one of the most common mental disorders with 
many studies reporting a lifetime prevalence of between 17% and 24% (Bijl et al., 1988, 
Jacobi et al., 2004, Kessler et al., 2003, Szadoczky et al., 1998). Whereas awareness and 
recognition of depression has increased (e.g. Highet et al., 2006; Dietrich et al., 2010), there is 
evidence that bipolar disorder (BD) is often not recognized and misdiagnosed (e.g. Hirschfeld 
et al., 2003a; Ghaemi et al., 1999;  Lish et al., 1994; Meyer & Meyer, 2009). The lifetime 
prevalence of bipolar I disorder is estimated at about 1%. However, recent studies emphasize 
that the bipolar spectrum, including bipolar II, bipolar NOS, and cyclothymia, might be more 
prevalent with about 5-9% depending on the criteria applied (e.g. Angst, 1998; Judd & 
Akiskal, 2003; Lewinsohn et al., 1995; Merikangas et al., 2007, Kessler et al., 1994; 
Zimmerman et al., 2009). 
Misdiagnoses can have severe consequences for the patients themselves (Oquendo et al., 
2000) as well as for society as a whole (Birnbaum et al., 2003; Matza et al., 2005). Shi and 
colleagues (2004) provided evidence that the risk of suicide attempts in people with 
unrecognized BD was significantly higher than it was in people with recognized BD. 
Furthermore, antidepressants are more likely to be prescribed than mood stabilizing 
medications (e.g. Birnbaum et al., 2003, Matza et al., 2005; Meyer & Meyer, 2009). There is 
evidence, however, that prescribing antidepressants to patients with BD can worsen the course 
of the illness (e.g. Altshuler et al., 1995; Ghaemi et al., 2000; Tondo, Vázquez &  
Baldessarini, 2010). Especially among people with an individual or family history of bipolar 
disorder, the use of antidepressants without mood stabilizing medication can trigger episodes 
of mania or hypomania and rapid cycling (Ghaemi et al., 2001). There are also wider social 
and economic consequences of misdiagnosis including medical costs and loss of productivity 
due to inability to work (e.g. Birnbaum et al., 2003; Matza et al., 2005). Therefore, adequate 
recognition of bipolar disorders is essential. 
Several instruments have been developed to screen for bipolar conditions. Some of them 
are aimed at the assessment of trait-like features and do not ask for symptoms within specific 
episodes (e.g., Depue et al., 1981; Eckblad & Chapman, 1986). Although these instruments 
are sometimes used to identify subjects with (sub-) affective disorders they are better 
understood as assessing risk factors for future bipolar disorders (e.g. Blechert & Meyer, 2005; 
Kwapil et al., 2000). Two tools specifically designed to screen for bipolar disorders have 
received a lot of interest and attention: the Mood Disorder Questionnaire (MDQ, Hirschfeld et 
al., 2000) and the Hypomania Checklist-32 (HCL-32, Angst et al., 2005). Both scales have 
been translated into several languages and have been evaluated (examples for the HCL-32: 
Angst et al., 2005, 2010, Vieta et al., 2007; for the MDQ: Jon et al., 2009; Tafalla et al., 
2009). In summary, most of those studies have provided evidence that both tools have 
sufficient sensitivity and specificity to detect bipolar disorders in samples of individuals with 
mood disorders. There are, however, still discussions about which algorithm and cut-off score 
might be most adequate when screening for bipolar disorders (e.g. Hirschfeld et al., 2003, 
Forty et al., 2009). In addition, Angst et al. (2005) developed the HCL-32 specifically with 
the goal of increasing the sensitivity for bipolar II disorder because they had concerns that the 
content of the items restricted the power of the MDQ to detect bipolar II or other 
subsyndromal bipolar conditions. Gervasoni et al. (2009) indeed found evidence that the 
sensitivity for bipolar II (45.8%) was lower when compared to bipolar I disorder (85%). Only 
two studies have reported data where both the HCL-32 and the MDQ were used in the same 
sample: Whereas Vieta et al. (2007) confirmed a significantly higher sensitivity of the HCL-
32 for bipolar disorder in general, Carta et al. (2006) drew the conclusion that the higher 
sensitivity was specifically due to bipolar II disorder. Although positive (PPP) and negative 
predictive power (NPP) are often considered clinically highly informative (e.g. Kraemer, 
1992), they are rarely reported. For the HCL-32 Angst et al (2005) and Forty et al. (2009) 
estimated PPP as 76% and NPP as 57% and 75% respectively. None of the MDQ studies 
mentioned above reported the equivalent values. Based on the tables provided by Tafalla et al 
(2009) and Gervasoni et al. (2009) including the frequencies for MDQ positive and negative 
screening cases, the estimates for PPP are 56.8 % and 62.2% and for NPP 96.2% and 84.2%.    
Overall the reported evidence supports the usefulness of these screening tools, but at least 
two issues have not been sufficiently addressed in prior research using screening tools for 
bipolar disorders. First of all, all studies have focused on patients with mood disorders. WE 
can therefore conclude that both MDQ and HCL-32 work fairly well in settings and clinics 
specializing in mood disorders. This, however, does not represent the majority of clinical 
services. Secondly, even if the comorbidity rates of the samples were reported, no one seemed 
to have looked at whether this affected the screening properties of the scales. The primary 
goal of the present study, therefore, was to evaluate the sensitivity and specificity of the HCL-
32 and MDQ in a sample of consecutively recruited patients with and without mood 
disorders. The secondary goal was to examine the effects of a comorbid Axis I and II disorder 
on the two measures in a sample of bipolar versus non-bipolar patients.    
 
Method 
Participants: Overall, 488 patients were recruited at seven different psychiatric clinics and 
outpatient clinics across Southern, Eastern, and Northern Germany after having provided 
written informed consent.   
The mean age was M = 39.22 years (SD = 13.37) with a range of 17 to 76. Three-hundred-
and sixty- six were women (62.7%). The distribution of the highest education achieved was as 
follows: 1.8% had no degree, 17.4% had a low level of education (‘Hauptschule’, 8 years), 
30.9% had a medium level of education (‘Mittlere Reife’, 10 years), 26.2% had completed 13 
years of secondary school (‘Abitur’), 12.1% had a university degree, and 11.7% either had not 
provided data or had obtained degrees abroad. The marital status of the majority was single (n 
= 251, 51.4%), 143 were married (28.3%), 53 participants were divorced (10.9%), seven (1.4 
%) were widowed, and 34 did not provide this information (7.0%). Two-hundred-and-twenty-
five participants were employed (46.1%), and ten individuals (2.0%) were retired. Twelve 
were students (2.5 %). Fifty-eight patients (11.9 %) were on disability benefits and an 
additional 85 patients (17.5 %) were unemployed. Ninety-eight individuals did not provide 
this information (20.1 %). 
Using the Structured Clinical Interview (see below), 140 patients had a diagnosis within 
the bipolar spectrum (28.7 %) and 348 (71.3 %) had a non-bipolar diagnosis (see for details 
and distribution of diagnoses: Table 1). The bipolar group consisted of 99 patients with 
bipolar I disorder, 33 patients with bipolar II disorder, 5 with cyclothymic disorder, and 3 
with schizoaffective disorder, bipolar subtype. The gender ratio was similar in the bipolar and 
the non-bipolar group, 2 (1, n = 388) = 1.97, n.s., but this was not the case when just looking 
at bipolar and unipolar disorders. As might be expected there were more women in the 
unipolar group, 2 (1, n = 298) = 4.98, p < .05, phi = .13. Marital status differed neither 
between bipolar and non-bipolar patients, 2 (2, n = 454) = 3.42, n.s., nor between bipolar and 
unipolar patients, 2 (2, n = 274) = 2.67, n.s.. The bipolar group was significantly younger than 
the non-bipolar group, t(480) = 3.39, p < .001, d = 0.34, but this was not the case when 
comparing the bipolar and the unipolar group, t(292) = 0.71, n.s., The bipolar patients reported 
an overall higher level of education, i.e. they completed 13 years of school or even graduated 
from university more often than all non-bipolar patients did, 2 (3, n = 431) = 11.81, p < .005. 
phi =.17, as well as the unipolar patients did, 2 (2, n = 253) = 11.86, p < .005. phi =.22. In 
addition, the bipolar group overall exhibited less Axis I and II comorbidity than all other 
patients as one group, 2 (1, n = 480) = 44.88, p < .001, phi = .31 (Table 1). This was also the 
case if one separately looked at comorbidity with Axis I or Axis II disorders and if one 
compared bipolar and unipolar disorders only (results not shown). 
Materials 
Hypomania Checklist 32 (HCL-32, Angst et al., 2005). This instrument consists of 32 
items for the self-assessment of hypomania. People are asked to remember “a period when 
you were in a ‘high’ (mood) and to indicate whether specific behaviors, thoughts, or emotions 
were present in such a state, e.g. ‘I need less sleep’, ‘I am less shy or inhibited’, or ‘I am more 
flirtatious and/or I am sexually more active’. The questionnaire also includes items about the 
duration of such ‘highs’. Furthermore, people are asked to rate the impact of such ‘highs’ as 
‘positive & negative’, ‘positive’, ‘no impact’, or ‘negative’ for family life, social life, and 
work. Additionally, other people’s reactions and comments on such episodes were assessed 
(positively, no comments, or negatively). These indicators were used to create an indicator of 
‘negative consequences’ by assigning each of the 5 items a score of ‘0’if it was a neutral 
response or ‘no impact’, a score of ‘1’ if it was a positive response as well as if negative 
consequences were mentioned, and a score of ‘2’ if only ‘negative consequences’ were 
pointed out.  
The checklist was first conceptualized in German by J. Angst and T.D. Meyer and then 
translated into several other languages with appropriate re-translation procedures as checks. 
The German version has been evaluated in three non-clinical samples (Brand et al., 2007; 
Holtman et al., 2009; Meyer et al., 2007) and one unpublished clinical study (Katzmann, 
2007) with all showing similar psychometric and factorial properties compared with other 
studies (e.g. Angst et al., 2005; Vieta et al., 2006).  
Mood Disorder Questionnaire (MDQ, Hirschfeld et al., 2000; German: Hautzinger & 
Meyer, 2002). The MDQ is a self-report screening instrument that screens for a lifetime 
history of manic episodes. It was originally derived from the DSM-IV and clinical experience. 
It uses a yes-no format for the 13 items. In addition, two questions ask whether symptoms 
have occurred in the same period of time and whether there was any impairment (answered on 
a 4-point scale) associated with these symptoms. The translation into German followed 
standard procedures. However, the German version has not yet been empirically evaluated on 
its own.  
Structured Clinical Interview for DSM-IV (SCID, First et al., 1996; German version: 
Wittchen, Zaudig, & Fydrich, 1997). The SCID was used to assess symptoms of DSM-IV 
(APA, 1994)  criteria for mental disorders. This interview was chosen on the basis of its 
accepted and widespread international use. All interviewers had been trained on their sites 
before the study and had sufficient clinical experience. In one center (Tübingen), we had 
randomly re-assessed 49 patients as part of a randomized control trial for bipolar disorder, and 
a high inter-rater reliability was found, e.g.  = .95 for bipolar I disorder,  = .89 for bipolar II 
disorder, and  = .95 for any of the anxiety disorders.  
Procedures.  
The study was approved by the ethics committee of the German Association of Psychology 
(DGPs) and the Review Board of the Ludwig Maximilian University Hospital, Munich. 
Psychologists and psychiatrists from the seven German centres (Berlin, Chemnitz, Dresden, 
Freiburg Hamburg, Munich, Tübingen) who were clinically trained and who had received 
prior training in using the SCID interviewed the patients without knowledge of the scores on 
the HCL-32 and the MDQ. The two self-rating scales were independently completed by the 
patients.  
All statistical analyses were done using SPSS17. Sample sizes varied for the MDQ and the 
HCL-32 because the data gathering for the MDQ had started earlier in one center (i.e. 
Tübingen) as part of the routine screening. Furthermore, sample sizes varied due to missing 
data. Except for specific comparisons between bipolar I and II patients, we decided to 
consider diagnostic groups separately only if they included at least 40 patients to maintain 
sufficient power for specific subgroup analyses. For all other analyses, all bipolar patients and 
non-bipolar patients were collapsed into two groups. 
 
 Results 
 
Reliability and correlates. Table 2 provides the means (SD) for HCL-32 total score, HCL-
32 subscales and MDQ, as well as the number of cases who scored above and below the cut-
offs for all groups. The reliability estimates were all satisfactory with   .79 (see Table 3). 
Age was unrelated to MDQ and HCL-32 scores. Current mood measured with the 7-point 
scale provided in the HCL-32 was significantly associated with the MDQ scores and with the 
HCL-32 subscale ‘harmful’, with better mood being related to higher MDQ and higher HCL 
harmful subscale scores. The interpretation of the HCL-32 subscales was supported by their 
association with the extent of negative consequences. Scores on both the HCL-32 and the 
MDQ covered the whole range of possible scores. Males had significantly higher scores than 
women on the MDQ, vs. 6.86 [SD = 4.09] vs. M = 5.97 [SD = 4.15], t (438) = 2.21, p < .05, 
and the HCL-32, M = 18.16 [SD = 6.67] vs. M = 16.49 [SD = 7.24] , t(359) = 2.20, p < .05, 
but in both cases these were only small to medium effect sizes, d = .22 and d = .24 
respectively. When differentiating between low, medium, and high education level, the two 
scales showed a different pattern. The level of education did not show any effect on MDQ 
scores, F(2, 383) = 0.11, n.s., but on HCL-32 scores, F(2, 311) = 4.12, p < .05, partial eta2 = 
.026. Post hoc effects revealed that those with the highest education significantly differed 
from those with low education, on average, scoring 3.03 points higher. 
Screening quality. In Table 4, the probabilities of a positive screening among those with a 
bipolar diagnosis (‘sensitivity’) compared to the ones among those with a unipolar depression, 
anxiety disorder, psychotic disorder, or all non-bipolar diagnoses combined are reported. 
Similarly, the probabilities of negative screening (‘specificity’) among those with a non-
bipolar disorder are mentioned. Additionally, the probability of a bipolar diagnosis among 
those screened as positive (‘positive predictive power’) and the probability of a non-bipolar 
diagnosis among those screened as negative (‘negative predictive power’), as well as the ‘area 
under the curve’ (AUC) from Receiver Operating Characteristic analyses are reported (see 
Kraemer, 1992). The 95 % confidence intervals of the AUCs overrlapped in all cases 
suggesting similar overall screening qualities of the HCL-32 and MDQ. In summary, 
sensitivity of the HCL-32 was always slightly higher, but in most cases specificity was clearly 
higher for the MDQ. The highest sensitivity of .90 is seen for bipolar II disorder using the 
HCL-32. 
Potential effect of comorbid conditions.  In Table 1, the rates of comorbidity for any Axis I 
or Axis II disorder or any comorbid mental health problem are displayed. Conducting a two-
factor ANOVA for the HCL-32 with the factors ‘bipolar vs. non-bipolar’ and ‘with vs. 
without any comorbidity’, as expected, revealed a highly significant effect for the factor 
‘bipolar’, F(1, 352) = 73.79, p < .001, partial eta2 = .175. ‘Comorbidity’ had a significant, 
though small effect as well, F(1, 352) = 3.95, p < 05, partial eta2 = .011. Most importantly, 
there was no significant interaction. F(1, 352) = 2.33, n.s., partial eta2 = .077. The estimated 
marginal HCL-32 means for those without any comorbid condition was 17.31 (SE = 0.50) and 
for those with a comorbid disorder 18.83 (SE = 0.58). Repeating the same analysis for the 
MDQ also revealed a highly significant effect for the factor ‘bipolar’, F(1, 431) = 147.17, p < 
.001, partial eta2 = .256. ‘Comorbidity’ also led to a significant effect, F(1, 431) = 8.84, p < 
.01, partial eta2 = .020. Most importantly again there was no significant interaction. F(1, 431) 
= 0.97, n.s., partial eta2 = .002. The estimated marginal means for those without any 
comorbid condition was 17.31 (SE = 0.50) and for those with a comorbid disorder 18.83 (SE 
= 0.58). The estimated marginal MDQ means for those without a comorbid condition was 
6.57 (SE = 0.27) and for those with a comorbid disorder 7.77 (SE = 0.30). 
We also ran categorical analyses using the published cut-off scores for the HCL-32 and the 
MDQ testing whether comorbidity affected rates of positive screens regardless of bipolar 
disorders. The presence or absence of a comorbid Axis I disorder did not significantly change 
the rate of positive screens in neither the HCL-32, 2 (1, n = 353) = 1.72, n.s., nor the MDQ, 2 
(1, n = 435) = 3.06, p < .10. Looking specifically at comorbidity with Axis II disorders, the 
same non-significant results emerged, HCL-32: 2 (1, n = 356) = 0.54, n.s., MDQ: 2 (1, n = 
435) = 0.79, n.s.. Including the presence of any comorbid disorder also did not affect the rate 
of positive screens for the HCL-32, 2 (1, n = 353) = 1.47, n.s., or MDQ, 2 (1, n = 432) = 0.15, 
n.s. 
 
Discussion 
 
In this study, we used a mixed sample of psychiatric patients to achieve two goals. Firstly, 
we evaluated the sensitivity, specificity, positive and negative predictive power of two 
internationally widely used screening tools for a lifetime history of hypomania or mania, the 
HCL-32 and the MDQ, in a sample which did not solely focus on patients with unipolar 
depression and bipolar disorders. Secondly, we examined whether a comorbid mental health 
problem would affect the screening properties of the two scales. Overall, we found similar 
results as other studies regarding the sensitivity for bipolar disorders, with the HCL- 32 
always being slightly more sensitive than the MDQ, especially for bipolar II disorders. 
Specificity, i.e. the probability to correctly identify the non-bipolar cases, varied 
tremendously between 26 % and 68 % with the worst result for the category ’psychotic 
disorders’ and with the HCL-32 always doing less well than the MDQ.  Even when compared 
to others studies, specificity for the HCL-32 was generally lower (e.g. Angst et al., 2005: 
Vieta et al., 2007; Wu et al., 2008). With respect to comorbidity we found that any 
comorbidity, regardless of whether it was an Axis I or II comorbidity, led dimensionally to a 
significant increase in both HCL-32 and MDQ scores but this did not significantly affect the 
rates of patients screened positively using the published cut-off scores of 14 for the HCL-32 
and 7 for the MDQ. 
This is the first study providing evidence that the HCL-32 and the MDQ might be useful as 
tools to screen for bipolarity not only in a sample of mood-disordered or unipolar-depressed 
patients, as originally intended (e.g., Angst et al., 2005), but also more generally in a wider 
context of psychiatry. For anxiety disorders we were even able to demonstrate this as a 
distinct group. As mentioned, the specificity of the HCL-32 was always lower that the one of 
the MDQ and both were lower than the ones in other studies (e.g. Angst, et al., 2005: 
Hirschfeld et al., 2003; Vieta et al., 2007; Weber Rouget et al., 2009). The question is why 
this might be the case. One explanation could be that the SCID interviews were not done 
reliably. We had reliability estimates only for the Tübingen center which were excellent. One 
could question whether reliability between centers would have varied, and we cannot discount 
this argument. Given that most clinicians are neither trained nor use a structured clinical 
interview in their routine practice, however, these results about sensitivity and specificity 
might even be more generalizable with regards to the usefulness of the HCL-32 and MDQ 
than those from prior studies which controlled for these factors. In addition, we consecutively 
included patients regardless of their diagnosis, especially those with a non-mood disorder, and 
this did not seem to have had a consistent negative effect on specificity. Another important 
difference between the current study and those being published about the HCL-32 is that we 
relied strictly on DSM-IV criteria for bipolar II disorder whereas most others relied on the 
more relaxed Zurich criteria (e.g. Angst et al., 2005; Wu et al., 2008). Although it is debatable 
whether the DSM-IV criteria which includes the artificial duration criterion of 4 days and 
excludes ‘overactivity’ as a core criterion is appropriate (e.g. Angst et al., 2003, Benazzi, 
2009, Dunner, 2003), we adhered to these criteria for this study. This definitely had an effect 
on the rate of diagnosed bipolar II disorders in our sample. A lower rate of sub-threshold 
hypomanic episodes might therefore have contributed to a lower specificity given that these 
cases are classified as non-bipolar patients according to the DSM-IV. Given that many 
clinicians in routine care currently do not diagnose bipolar II disorder according to these more 
liberal research criteria, we feel that our data are of relevance for everyday practice. 
Comorbidity is frequent in psychiatry (e.g. Goodwin & Jamison, 2007), which is also 
reflected in the present sample with 59 % having at least one comorbid condition. It seemed 
essential to evaluate whether the presence or absence of a comorbid mental health problem 
would affect the screening for bipolarity. We were able to show that whereas comorbidity is 
generally associated with higher scores on the MDQ and the HCL-32, there was no 
interaction of ‘(non-) bipolar disorder’ and ‘comorbidity’. This implies that there was no 
systematic trend that patients who had no bipolar disorder but reported comorbid conditions 
would exceed the HCL-32 or MDQ scores of patients with bipolar disorder. Additionally, 
these increases do not seem large enough to seriously affect the percentage of positive 
screens.  
Before drawing final conclusions, several methodological limitations of the present study 
have to be kept in mind. Some of the limitations such as the lack of a formal reliability testing 
across centers, the use of the formal DSM-IV bipolar II disorder category which renders 
comparison with other studies more difficult have already been mentioned before. A further 
limitation is that we recruited sufficiently large groups of patients with only anxiety disorders 
and non-affective psychotic disorders to make direct comparisons but ended up with low 
numbers of individuals with, for example, primary substance use disorders or eating disorders 
to allow separately testing specificity for those diagnostic categories.     
Conclusions. Despite these limitations we think that our data show that both the HCL-32 
and the MDQ are sufficiently sensitive instruments to screen for a lifetime history of mania or 
hypomania, even under conditions of routine psychiatric care. Nevertheless, they do not 
replace a thorough clinical assessment and interview. They also do not solve issues such as 
the effect of the salience or weighing of certain symptoms (e.g. Cooper & Balsis, 2009; 
Meyer et al., 2004) or information processing biases in the assessment process such as the use 
of prototypes or implicit theories (e.g. Bruchmüller & Meyer, 2009; Meyer et al., 2010). The 
use of the HCL-32 and the MDQ might, however, help reducing their impact and avoiding 
under- and over-diagnosis of bipolar disorder (e.g. Zimmerman et al, 2008, 2010). 
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ile
d).
 
*
.
 
 
p 
<
 
.
05
 
(2-
ta
ile
d).
 
          
Ta
bl
e 
4:
 
 
Se
n
si
tiv
ity
, 
s
pe
ci
fic
ity
, 
po
si
tiv
e,
 
a
n
d 
n
e
ga
tiv
e 
pr
ed
ic
tiv
e 
po
w
er
 
an
d 
Ar
ea
 
Un
de
r 
Cu
rv
e 
(A
UC
)  
fo
r 
th
e 
pu
bl
is
he
d 
H
CL
-
32
 
a
n
d 
M
D
Q 
cu
t-o
ffs
 
fo
r 
bi
po
la
r 
di
s
o
rd
er
s 
co
m
pa
re
d 
to
 
o
th
er
 
c
at
eg
o
rie
s 
 
 
 
 
SE
 
 
SP
 
PP
P 
 
N
PP
 
AU
C 
[C
I 9
5 
%
] 
Bi
po
la
r 
ve
rs
u
s 
 
H
CL
-
32
 
.
88
 
.
36
 
.
40
 
.
86
 
.
75
 
 
[.6
9-
.
81
] 
n
o
n
-
bi
po
la
r 
M
D
Q 
.
80
 
.
64
 
.
47
 
.
89
 
.
81
 
[.7
6-
.
86
] 
Bi
po
la
r 
ve
rs
u
s 
 
H
CL
-
32
 
.
88
 
.
41
 
.
60
 
.
77
 
.
77
 
 
[.7
1-
.
83
] 
Un
ip
o
la
r 
M
D
Q 
.
80
 
.
68
 
.
68
 
.
80
 
.
83
 
 
[.7
8-
.
88
] 
Bi
po
la
r 
I v
e
rs
u
s 
H
CL
-
32
 
.
87
 
.
39
 
.
52
 
.
80
 
.
80
 
[.7
3-
.
87
] 
Un
ip
o
la
r 
M
D
Q 
.
84
 
.
69
 
.
65
 
.
87
 
.
87
 
[.8
2-
.
92
] 
Bi
po
la
r 
II 
ve
rs
u
s  
H
CL
-
32
 
.
90
 
.
39
 
.
31
 
.
93
 
.
73
 
[.6
2-
.
84
] 
Un
ip
o
la
r 
M
D
Q 
.
83
 
.
69
 
.
37
 
.
95
 
.
82
 
[.7
4-
.
90
] 
Bi
po
la
r 
ve
rs
u
s 
H
CL
-
32
 
.
88
 
.
43
 
.
76
 
.
63
 
.
76
 
[.7
1-
.
81
] 
An
xie
ty
 
M
D
Q 
.
80
 
.
68
 
.
80
 
.
68
 
.
84
 
[.7
9-
.
89
] 
Bi
po
la
r 
ve
rs
u
s 
H
CL
-
32
 
.
88
 
.
26
 
.
76
 
.
44
 
.
69
 
 
[.6
1-
.
78
] 
Ps
yc
ho
se
s 
M
D
Q 
.
80
 
.
44
 
.
80
 
.
44
 
.
69
 
[.6
0-
.
78
] 
 N
o
te
s:
 
SE
 
=
 
Se
n
si
tiv
ity
,
 
SP
 
=
 
Sp
e
cif
ic
ity
,
 
PP
P 
=
 
Po
si
tiv
e
 
Pr
e
di
ct
ive
 
Po
w
e
r,
 
N
PP
 
=
 
N
e
ga
tiv
e
 
Pr
e
di
ct
ive
 
Po
w
e
r,
 
AU
C 
=
 
Ar
e
a
 
u
n
de
r 
th
e 
cu
rv
e
 
(R
O
C)
,
 
CI
 
=
 
95
 
%
 
co
n
fid
en
ce
 
in
te
rv
a
l f
o
r 
AU
C,
 
M
D
Q 
–
 
M
o
od
 
D
is
o
rd
e
r 
Qu
es
tio
n
n
a
ire
,
 
H
CL
-
32
 
–
 
Hy
po
m
a
n
ia
 
Ch
e
ck
lis
t-3
2.
 
 
 
